<code id='0067D0A3B2'></code><style id='0067D0A3B2'></style>
    • <acronym id='0067D0A3B2'></acronym>
      <center id='0067D0A3B2'><center id='0067D0A3B2'><tfoot id='0067D0A3B2'></tfoot></center><abbr id='0067D0A3B2'><dir id='0067D0A3B2'><tfoot id='0067D0A3B2'></tfoot><noframes id='0067D0A3B2'>

    • <optgroup id='0067D0A3B2'><strike id='0067D0A3B2'><sup id='0067D0A3B2'></sup></strike><code id='0067D0A3B2'></code></optgroup>
        1. <b id='0067D0A3B2'><label id='0067D0A3B2'><select id='0067D0A3B2'><dt id='0067D0A3B2'><span id='0067D0A3B2'></span></dt></select></label></b><u id='0067D0A3B2'></u>
          <i id='0067D0A3B2'><strike id='0067D0A3B2'><tt id='0067D0A3B2'><pre id='0067D0A3B2'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:96118
          Mathai Mammen headshot
          FogPharma CEO Mathai Mammen Venrock

          SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

          Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

          advertisement

          FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCJapanesedrugmakerNipponShinyakusaidon

          read more
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more

          The Bio Revolution is changing business and society

          Culturedmeatismadeusingtissue-culturetechnology,alabprocessbywhichanimalcellsaregrowninvitro.Zhdanov